Acinetobacter Pneumonia Therapeutics Market: By Drug Class (Cephalosporins, Fluoroquinolone, Glycylcycline, Carbapenem, β-Lactam antibiotics, Sulbactam, Aminoglycoside, Polymyxins, Tetracycline, Sulfonamide, and others), By Route of Administration (Oral, Intravenous, and Others), and By Geography

Acinetobacter Pneumonia Therapeutics Market size was valued at USD 437.5 million and is poised to grow at CAGR of 7.5% from 2024-2030. The Acinetobacter pneumonia therapeutics market encompasses the development and sale of drugs targeting pneumonia caused by Acinetobacter bacteria, known for their resistance to multiple antibiotics. These bacteria can cause a variety of healthcare-associated infections and are emerging as important pathogens globally. The Acinetobacter pneumonia therapeutics market is poised to see steady growth over the coming years. The growing prevalence of drug-resistant infections along with rising cases of hospital-acquired pneumonia are some of the key drivers propelling the demand for novel treatment options.

The desire for innovative therapeutic solutions fuels the pharmaceutical industry’s research and development operations. Furthermore, favourable government policies have supported pharmaceutical manufacturers in commercializing innovative drugs. Rising healthcare spending has enabled affordable access to diagnostic kits and therapies for pneumonia patients. The growing medical tourism industry has further augmented the availability of diagnostic and treatment options. However, the lack of approved therapeutics continues to be a challenge, with antibiotics being the primary treatment choice.

Acinetobacter Pneumonia Therapeutics Market:

• In April 2024, The European Commission approved Pfizer's EMBLAVEO® for patients with multidrug-resistant infections and limited treatment options.
• In 2023, researchers created Zosurabalpin, a novel antibiotic that can destroy drug-resistant germs. Zosurabalpin inhibits the passage of giant molecules known as lipopolysaccharides to the outer membranes of Acinetobacter baumannii bacteria, causing them to concentrate within the cell. Zosurabalpin has shown promise in fighting pneumonia and sepsis strains in mice, and it may be able to eliminate one of three bacteria thought to pose the greatest threat to human health due to medication resistance.
• On April 2023, Innoviva Inc., a diversified holding company with a portfolio of royalties and other healthcare assets, announced that the U.S. Food and Drug Administration’s (FDA) Antimicrobial Committee (AMDAC) unanimously voted 12-0 in support of approval based on a favourable benefir-risk assessment of sulbactam-durlobactam for the treatment of adults with hospital -acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by susceptible strains of Acinetobacter baumannii-calcoaceticus complex (Acinetobacter)